DAVENPORT & Co LLC Buys 3,587 Shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS)

DAVENPORT & Co LLC lifted its stake in Fresenius Medical Care AG & Co. KGaA (NYSE:FMSGet Rating) by 28.8% in the 1st quarter, HoldingsChannel reports. The fund owned 16,021 shares of the company’s stock after purchasing an additional 3,587 shares during the quarter. DAVENPORT & Co LLC’s holdings in Fresenius Medical Care AG & Co. KGaA were worth $540,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in FMS. Creative Financial Designs Inc. ADV acquired a new position in Fresenius Medical Care AG & Co. KGaA during the 1st quarter valued at about $67,000. GHP Investment Advisors Inc. acquired a new position in Fresenius Medical Care AG & Co. KGaA during the 1st quarter valued at about $72,000. Signaturefd LLC increased its position in Fresenius Medical Care AG & Co. KGaA by 26.4% during the 1st quarter. Signaturefd LLC now owns 2,190 shares of the company’s stock valued at $74,000 after buying an additional 458 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its position in Fresenius Medical Care AG & Co. KGaA by 223.0% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 3,976 shares of the company’s stock valued at $129,000 after buying an additional 2,745 shares in the last quarter. Finally, Johnson Financial Group Inc. acquired a new position in Fresenius Medical Care AG & Co. KGaA during the 4th quarter valued at about $155,000. 4.73% of the stock is owned by institutional investors.

Fresenius Medical Care AG & Co. KGaA Stock Down 0.1 %

Shares of FMS opened at $22.76 on Tuesday. Fresenius Medical Care AG & Co. KGaA has a 52 week low of $22.09 and a 52 week high of $41.38. The company has a quick ratio of 0.93, a current ratio of 1.26 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $13.34 billion, a price-to-earnings ratio of 13.01, a PEG ratio of 0.92 and a beta of 1.21. The stock’s 50-day moving average price is $26.25 and its 200-day moving average price is $30.44.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMSGet Rating) last issued its earnings results on Wednesday, May 4th. The company reported $0.38 EPS for the quarter, topping analysts’ consensus estimates of $0.30 by $0.08. Fresenius Medical Care AG & Co. KGaA had a return on equity of 6.99% and a net margin of 4.91%. The firm had revenue of $5.10 billion for the quarter, compared to the consensus estimate of $4.97 billion. On average, sell-side analysts predict that Fresenius Medical Care AG & Co. KGaA will post 1.89 EPS for the current year.

Fresenius Medical Care AG & Co. KGaA Cuts Dividend

The business also recently announced an annual dividend, which was paid on Friday, May 27th. Stockholders of record on Monday, May 16th were paid a $0.7093 dividend. The ex-dividend date of this dividend was Friday, May 13th. This represents a dividend yield of 3.4%. Fresenius Medical Care AG & Co. KGaA’s payout ratio is 28.00%.

Analysts Set New Price Targets

FMS has been the topic of several recent analyst reports. StockNews.com lowered Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 15th. Jefferies Financial Group raised Fresenius Medical Care AG & Co. KGaA from an “underperform” rating to a “buy” rating and upped their target price for the company from $30.30 to $33.70 in a research report on Monday, June 27th. JPMorgan Chase & Co. increased their price objective on Fresenius Medical Care AG & Co. KGaA from €48.70 ($49.69) to €51.00 ($52.04) and gave the company an “underweight” rating in a report on Thursday, May 5th. Finally, Truist Financial cut their price objective on Fresenius Medical Care AG & Co. KGaA from $34.00 to $27.00 and set a “hold” rating on the stock in a report on Wednesday, June 22nd. One analyst has rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $52.51.

Fresenius Medical Care AG & Co. KGaA Profile

(Get Rating)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

See Also

Want to see what other hedge funds are holding FMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fresenius Medical Care AG & Co. KGaA (NYSE:FMSGet Rating).

Institutional Ownership by Quarter for Fresenius Medical Care AG & Co. KGaA (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.